In 2023, Douglas E. Onsi earned $1.10M in total compensation at Leap Therapeutics, Inc., including $675.00K salary and $368.04K bonus. Most recently acquired 571,428 shares in Feb 2019. Currently holds stock worth $4.69M. 5+ years at the helm of Leap Therapeutics, Inc..
Compensation History
Annual executive compensation data for Douglas E. Onsi, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.10M
Salary
$675.00K
Bonus
$368.04K
Other
$58.06K
Salary
$675.00KBoard Justification
The executive compensation program is designed to attract and retain a highly skilled team of key executives and to align the compensation of our executives with the interests of our stockholders by rewarding the achievement of short- and long-term strategic financial goals.
Bonus
$368.04KBoard Justification
This column represents the cash incentive bonus payments for 2023 made to each executive, based on the achievement of corporate objectives established by the Board.
Other Compensation
$58.06KBoard Justification
Other compensation includes 401(k) matching, payment of medical and dental insurance, Company HSA contribution, life insurance, and Paid Medical Leave.
Restricted Stock
Board Justification
No stock was vested in 2023 as the focus is on cash compensation and not on stock grants or options.
Performance Metrics
The corporate objectives for 2023 included completion of enrollment in the 160 patient randomized controlled Part C of the DisTinGuish study, the completion of enrollment in the 33 patient Part A of the DeFianCe study, development of a new manufacturing process for our DKN-01 monoclonal antibody, and generating preclinical data for the early stage pipeline.
Douglas E. Onsi
CEO of Leap Therapeutics, Inc.
Education
B.S. in Finance from University of Michigan
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
January 1, 1974 - 51 years ago
CEO of Leap Therapeutics, Inc. for
5 years 8 months (Apr 2020 - Present)
Previous Experience
Chief Financial Officer, Treasurer and Secretary of Leap Therapeutics, Inc.
Other Leap Therapeutics, Inc. CEOs
Holdings
Track Douglas E. Onsi's stock holdings and portfolio value over time.
Insider Trading
Douglas E. Onsi's recent stock transactions, purchases, and sales filed with the SEC.
$1.00M
LPTX at $1.75/share
Feb 5, 2019
Purchase
$6.44M
LPTX at $6.09/share
Nov 14, 2017
Purchase
Rivals
Compare Douglas E. Onsi with competitor CEOs and industry peers.